VM 200

Drug Profile

VM 200

Alternative Names: VM200

Latest Information Update: 08 Jan 2016

Price : $50

At a glance

  • Originator Case Western Reserve University
  • Developer Vision Medicines
  • Class Amines; Eye disorder therapies; Small molecules
  • Mechanism of Action Aldehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn error metabolic disorders; Macular degeneration; Sjogren-Larsson syndrome; Stargardt disease

Most Recent Events

  • 08 Jan 2016 Preclinical trials in Macular degeneration in USA (PO) before January 2016
  • 08 Jan 2016 Preclinical trials in Sjogren-Larrson syndrome in USA (PO) before January 2016
  • 08 Jan 2016 Preclinical trials in Inborn error metabolic disorders in USA (PO) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top